Document is current
Any future updates will be listed below
-
Authors
Izzo, Franco https://orcid.org/0000-0002-5813-6504
Myers, Robert M. https://orcid.org/0000-0003-1869-6467
Ganesan, Saravanan
Mekerishvili, Levan https://orcid.org/0000-0002-4792-5356
Kottapalli, Sanjay
Prieto, Tamara
Eton, Elliot O. https://orcid.org/0000-0002-8980-9310
Botella, Theo
Dunbar, Andrew J.
Bowman, Robert L.
Sotelo, Jesus
Potenski, Catherine
Mimitou, Eleni P. https://orcid.org/0000-0001-9737-6394
Stahl, Maximilian
El Ghaity-Beckley, Sebastian
Arandela, JoAnn
Raviram, Ramya
Choi, Daniel C. https://orcid.org/0000-0003-3406-9113
Hoffman, Ronald
Chaligné, Ronan https://orcid.org/0000-0003-4332-3291
Abdel-Wahab, Omar https://orcid.org/0000-0002-3907-6171
Smibert, Peter https://orcid.org/0000-0003-0772-1647
Ghobrial, Irene M. https://orcid.org/0000-0001-7361-3092
Scandura, Joseph M. https://orcid.org/0000-0002-9525-143X
Marcellino, Bridget
Levine, Ross L. https://orcid.org/0000-0002-7884-1905
Landau, Dan A. https://orcid.org/0000-0003-2346-9541
- License Information
-
More Information
Article History
Received: 22 May 2022
Accepted: 4 April 2024
First Online: 8 May 2024
Competing interests
: M.S. served on the advisory board for Novartis, Kymera, Sierra Oncology, GSK, Rigel, BMS and Taiho; consulted for Boston Consulting and Dedham group and participated in GME activity for Novartis, Curis Oncology, Haymarket Media and Clinical care options. R.H. has served as a consultant for Protagonist Therapeutics, received research funding from Kartos Therapeutics, Novartis and AbbVie, and is on the data safety monitoring board of Novartis and AbbVie. O.A.-W. has served as a consultant for H3B Biomedicine, Foundation Medicine, Merck, Pfizer, Codify Therapeutics and Janssen, and is on the scientific advisory board of Envisagenics, AIChemy and Codify Therapeutics. O.A.-W. has received previous research funding from H3B Biomedicine, LOXO Oncology, Nurix Therapeutics, Codify Therapeutics and Minovia unrelated to the current work. O.A.-W. is a scientific co-founder of Codify Therapeutics. P.S. and E.P.M. are current employees of 10x Genomics and Immunai, respectively. R.L.L. is on the supervisory board of Qiagen and is a scientific advisor to Imago, Mission Bio, Bakx, Zentalis, Ajax, Auron, Prelude, C4 Therapeutics and Isoplexis. R.L.L. has received research support from Abbvie, Constellation, Ajax, Zentalis and Prelude. R.L.L. has received research support from and consulted for Celgene and Roche and has consulted for Syndax, Incyte, Janssen, Astellas, Morphosys and Novartis. R.L.L. has received honoraria from Astra Zeneca and Novartis for invited lectures and from Gilead and Novartis for grant reviews. D.A.L. has served as a consultant for Abbvie and Illumina and is on the scientific advisory board of Mission Bio and C2i Genomics. D.A.L. has received previous research funding from BMS, 10x Genomics and Illumina unrelated to the current work. R.M.M., F.I., E.P.M., R.C., P.S. and D.A.L. have filed a patent for GoT–ChA (63/288,874). The other authors declare no competing interests.
